Could Better Blood Sugar Control Help With Diabetic Nerve Pain? A New Study Is Testing It

Painful diabetic neuropathy (PDN) is nerve damage caused by diabetes that leads to pain, often in the feet and legs. It is a common complication that significantly affects quality of life and creates real hardship for people living with diabetes. Despite being widespread, treatment options remain limited, which is why researchers are exploring new approaches.

For years, the focus has been on keeping average blood sugar levels in a healthy range. But emerging evidence suggests something else may matter too: how much blood sugar bounces up and down throughout the day. Scientists call this 'glycaemic variability,' and new research hints it might be connected to pain flare-ups in people with nerve damage.

Hybrid closed-loop (HCL) insulin pump systems are designed to automatically adjust insulin delivery based on continuous glucose monitor readings. This technology aims to keep blood sugar levels more stable by reducing the dramatic ups and downs that happen with standard insulin therapy.

If blood sugar swings truly trigger pain spikes, then technology that smooths out those swings might help reduce pain intensity. This is the central question the PAINLESS trial is designed to answer.

The PAINLESS study is a randomised crossover trial involving 49 adults with type 1 diabetes and painful diabetic neuropathy at two centres. Each participant will spend 12 weeks using standard continuous glucose monitoring and insulin, then switch to 12 weeks using a hybrid closed-loop system (Tandem t:slim X2 with Control-IQ technology). The order is randomised so researchers can fairly compare both approaches.

The main question: Does pain intensity improve during the hybrid closed-loop period compared to standard care? Researchers will ask participants to rate their daily pain on a scale from 0 to 10 and track it over 7-day periods. They'll also measure whether pain relief lasts and whether it meaningfully improves people's ability to function and their overall quality of life.

Beyond pain scores, the trial will look at mood, emotional health, and physical function using validated surveys. Researchers will also use specialised nerve tests to understand how nerve function may change with either approach.

If this trial shows that more stable blood sugar control reduces nerve pain, it could open a new reason to consider hybrid closed-loop technology—beyond the well-known benefit of better average glucose control. It might also help researchers understand the relationship between blood sugar variability and pain, which could lead to other treatment ideas.

This is an early-stage investigation, not yet proven. The results will help clarify whether blood sugar stability truly affects pain and whether the technology can deliver meaningful relief for people struggling with this painful complication.

Source: PloS one. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.